Loading...
XKRX003000
Market cap215mUSD
Dec 24, Last price  
4,595.00KRW
1D
-1.82%
1Q
-9.01%
Jan 2017
-75.11%
Name

Bukwang Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:003000 chart
P/E
P/S
2.50
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
4.20%
Rev. gr., 5y
-8.30%
Revenues
125.93b
-34.04%
137,523,643,000155,670,536,000161,578,385,000170,810,033,000180,621,167,000101,218,841,170147,525,248,350130,794,936,620141,687,310,090142,132,090,470138,617,593,780150,743,453,790194,223,518,400168,193,616,060169,659,753,510182,491,221,470190,909,364,530125,928,240,770
Net income
-31.33b
L+637.40%
19,546,836,00032,820,365,00030,880,035,00027,873,116,00027,394,121,0006,406,124,93016,511,914,53019,532,034,47023,616,206,94025,139,405,30015,807,434,67011,090,626,650145,670,056,220-7,434,843,160-10,104,662,060-2,796,797,660-4,248,677,010-31,329,660,640
CFO
-10.50b
L
23,265,988,00027,874,618,000-2,748,946,00015,417,164,00033,565,101,00033,120,756,53049,499,634,11036,515,220,60027,862,826,03010,297,553,570-7,763,106,3508,562,581,7206,816,640,980-23,407,507,620723,168,74026,524,994,28016,461,450,020-10,500,408,027
Dividend
Dec 29, 2021100 KRW/sh
Earnings
Feb 06, 2025

Profile

Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
IPO date
Aug 05, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
125,928,241
-34.04%
190,909,365
4.61%
182,491,221
7.56%
Cost of revenue
136,917,436
155,577,113
142,691,771
Unusual Expense (Income)
NOPBT
(10,989,195)
35,332,251
39,799,451
NOPBT Margin
18.51%
21.81%
Operating Taxes
(5,162,874)
3,215,805
6,584,128
Tax Rate
9.10%
16.54%
NOPAT
(5,826,321)
32,116,447
33,215,322
Net income
(31,329,661)
637.40%
(4,248,677)
51.91%
(2,796,798)
-72.32%
Dividends
(6,845,467)
(6,225,071)
Dividend yield
1.14%
0.70%
Proceeds from repurchase of equity
(2,648,797)
(516,193)
BB yield
0.44%
0.06%
Debt
Debt current
217,604
242,909
444,171
Long-term debt
80,031,068
1,618,668
2,672,564
Deferred revenue
13,444,933
7,578,428
6,193,263
Other long-term liabilities
21,416,135
65,201,082
61,836,514
Net debt
(102,604,753)
(121,319,882)
(118,003,030)
Cash flow
Cash from operating activities
(10,500,408)
16,461,450
26,524,994
CAPEX
(2,814,665)
(4,990,210)
(789,522)
Cash from investing activities
(2,319,128)
(3,151,014)
4,749,354
Cash from financing activities
76,838,554
(10,397,839)
(27,484,627)
FCF
77,160,542
43,090,453
33,537,260
Balance
Cash
151,227,173
85,516,748
84,277,135
Long term investments
31,626,252
37,664,712
36,842,630
Excess cash
176,557,013
113,635,991
111,995,204
Stockholders' equity
270,138,599
506,556,705
514,711,721
Invested Capital
145,065,761
225,016,827
230,106,278
ROIC
14.11%
14.19%
ROCE
10.10%
11.26%
EV
Common stock shares outstanding
68,455
68,455
68,460
Price
6,100.00
-30.29%
8,750.00
-32.17%
12,900.00
-54.09%
Market cap
417,573,493
-30.29%
598,978,371
-32.18%
883,138,373
-54.21%
EV
522,344,475
486,288,571
775,588,557
EBITDA
(6,696,757)
40,448,781
44,642,207
EV/EBITDA
12.02
17.37
Interest
3,807,575
1,760,302
1,408,313
Interest/NOPBT
4.98%
3.54%